Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose
{"title":"乳铁蛋白作为预防和治疗严重急性呼吸系统综合征冠状病毒2型感染的可能药物","authors":"Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose","doi":"10.20965/jdr.2023.p0027","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.","PeriodicalId":46831,"journal":{"name":"Journal of Disaster Research","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection\",\"authors\":\"Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose\",\"doi\":\"10.20965/jdr.2023.p0027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.\",\"PeriodicalId\":46831,\"journal\":{\"name\":\"Journal of Disaster Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Disaster Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20965/jdr.2023.p0027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GEOSCIENCES, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Disaster Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20965/jdr.2023.p0027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GEOSCIENCES, MULTIDISCIPLINARY","Score":null,"Total":0}
Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.